Serum uric acid as a predictor of mortality and future exacerbations of COPD

European Respiratory Journal

Volumn 43, Issue 1, 2014, Pages 43-53

  Bartziokas, Konstantinos ^a   Papaioannou, Andriana I ^b   Loukides, Stelios ^c   Papadopoulos, Alexandros ^a   Haniotou, Aikaterini ^a   Papiris, Spyridon ^c   Kostikas, Konstantinos ^c  

^a AMALIA FLEMING GENERAL HOSPITAL   (Greece)

^b SISMANOGLIO HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

URIC ACID;

AGED; AIRWAY OBSTRUCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONINVASIVE VENTILATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; URIC ACID BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MULTIVARIATE ANALYSIS; POISSON DISTRIBUTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; URIC ACID;

EID: 84891909387     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00209212     Document Type: Review

References (41)

1. Vestbo J, Hurd SS, Agust́ AG, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
2. Soler-Cataluna JJ, Mart́nez-Garća MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931.
3. Fox IH. Metabolic basis for disorders of purine nucleotide degradation. Metabolism 1981; 30: 616-634.
4. Elsayed NM, Nakashima JM, Postlethwait EM. Measurement of uric acid as a marker of oxygen tension in the lung. Arch Biochem Biophys 1993; 302: 228-232.
5. Ruggiero C, Cherubini A, Ble A, et al. Uric acid and inflammatory markers. Eur Heart J 2006; 27: 1174-1181.
6. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821.
7. Saito H, Nishimura M, Shibuya E, et al. Tissue hypoxia in sleep apnea syndrome assessed by uric acid and adenosine. Chest 2002; 122: 1686-1694.
8. Voelkel MA, Wynne KM, Badesch DB, et al. Hyperuricemia in severe pulmonary hypertension. Chest 2000; 117: 19-24.
9. Aida Y, Shibata Y, Osaka D, et al. The relationship between serum uric acid and spirometric values in participants in a health check: The Takahata study. Int J Med Sci 2011; 8: 470-478.
10. Garcia-Pachon E, Padilla-Navas I, Shum C. Serum uric acid to creatinine ratio in patients with chronic obstructive pulmonary disease. Lung 2007; 185: 21-24.
11. Papadopoulos A, Bartziokas K, Haniotou A, et al. Serum uric acid and uric acid/creatinine ratio in exacerbations of COPD. Eur Respir J 2011; 38: Suppl. 55, 157s.
12. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-383.
13. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
14. Høiseth AD, Neukamm A, Karlsson BD, et al. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax 2011; 66: 775-781.
15. McGhan R, Radcliff T, Fish R, et al. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest 2007; 132: 1748-1755.
16. Aaron SD, Fergusson D, Marks GB, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 2008; 63: 122-128.
17. Pascual-Figal DA, Hurtado-Mart́nez JA, Redondo B, et al. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail 2007; 9: 518-524.
18. Hunninghake DB. Cardiovascular disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 44-49.
19. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome Lancet 2007; 370: 797-799.
20. Ruggiero C, Cherubini A, Miller E 3rd., et al. Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years. Am J Cardiol 2007; 100: 115-121.
21. Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185: 1065-1072.
22. Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 250-255.
23. Koutsokera A, Kiropoulos TS, Nikoulis DJ, et al. Clinical, functional and biochemical changes during recovery from COPD exacerbations. Respir Med 2009; 103: 919-926.
24. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest 2008; 134: 263-272.
25. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131: 1058-1067.
26. Steer J, Gibson J, Bourke SC. The DECAF Score: Predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax 2012; 67: 970-976.
27. Sato N, Kurashima K, Ubukata M, et al. [Prognostic significance of serum uric acid in patients with chronic obstructive pulmonary disease receiving home oxygen therapy]. Nihon Kokyuki Gakkai Zasshi 2003; 41: 74-80.
28. Nicks ME, O'Brien MM, Bowler RP. Plasma antioxidants are associated with impaired lung function and COPD exacerbations in smokers. COPD 2011; 8: 264-269.
29. Miravitlles M, Guerrero T, Mayordomo C, et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: A multiple logistic regression analysis. The EOLO Study Group. Respiration 2000; 67: 495-501.
30. Patel IS, Seemungal TA, Wilks M, et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57: 759-764.
31. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.
32. Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: Validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107: 1991-1997.
33. So A, Thorens B. Uric acid transport and disease. J Clin Invest 2010; 120: 1791-1799.
34. Filippatos GS, Ahmed MI, Gladden JD, et al. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: Potential mechanistic insights from epidemiological data. Eur Heart J 2011; 32: 712-720.
35. Demartini FE. Hyperuricemia induced by drugs. Arthritis Rheum 1965; 8: 823-829.
36. Kent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with COPD: Cause, effects, and disease progression. Int J Chron Obstruct Pulmon Dis 2011; 6: 199-208.
37. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: A systematic review and a meta-analysis. Thorax 2004; 59: 574-580.
38. Holme I, Aastveit AH, Hammar N, et al. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2009; 266: 558-570.
39. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: The Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005; 52: 283-289.
40. Choi HK, Curhan G. Beer, liquor, and wine consumption and serum uric acid level: The Third National Health and Nutrition Examination Survey. Arthritis Rheum 2004; 51: 1023-1029.
41. Yanbaeva DG, Dentener MA, Creutzberg EC, et al. Systemic inflammation in COPD: Is genetic susceptibility a key factor COPD 2006; 3: 51-61.